Literature DB >> 31849438

Key Factors in Antibiotic Resistance.

Vikas Yellapu1,2, Nicholas Roma3, Victoria Ngo3, Parampreet Kaur1, Richard Snyder4.   

Abstract

Entities:  

Year:  2019        PMID: 31849438      PMCID: PMC6906893          DOI: 10.4103/jgid.jgid_115_19

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


× No keyword cloud information.
Sir, Antibiotic resistance (AR) continues to be a public health concern that affects close to 2 million Americans each year.[12]In comparison to other nations, the United States is one among the highest consumers of broad-spectrum antibiotics with a minimum of 4.3 defined daily doses per person. When we consider the cumulative antibiotic dosage, it is approximately 10–20 daily doses per person.[34]Despite regulations regarding the antibiotic usage, we seem to be consuming antibiotics at an astounding rate. We know that continued prescribing of antibiotics increases the development of infections due to resistant pathogens. While your paper touched on the factors that need to be addressed in developing countries, we would like to mention factors that developed nations with high rates of AR should be addressed.

INCREASED ANTIBIOTICS RESEARCH

Recently, the United States had a shortage of penicillin G, an essential medication as listed by the World Health Organization.[56]While this deficit is resolved due to the increased production at the request of the Food and Drug Administration (FDA), such a shortage of an essential medication should not have occurred in the first place. This medication deficit was due to fewer pharmaceutical companies producing penicillin. Many pharmaceutical corporations no longer research and manufacture antibiotics due to a narrow profit margin.[7]Currently, only four major companies still have a designated “antibiotics division.” Pew Trusts reports that there are 42 new antibiotics in different phases of development, and only one of these is being produced by a large company with a sustainable supply chain.[8]Government entities need to provide incentives for larger companies to research and produce new antibiotics along with a strong supply chain to ensure a sustained production of essential antibiotics.

DECREASING THE USE OF ENVIRONMENTAL ANTIBIOTICS

The environmental use of antibiotics refers to using antibiotics in livestock. In 2015, it was noted that 70% of total ingested antibiotics actually came from the consumption of animal products.[9]Over the next decade, it is estimated that consumption of antibiotics from livestock will increase by roughly 70%.[1011]The FDA has made significant efforts in curbing the use of antibiotics in animals. For example, since 2017, it has been illegal to use “medically important” antibiotics for the growth of livestock. The FDA defines “medically important” antibiotics as those that are used frequently to treat human infections. Since the implementation of this law, there has been a 43% decrease in the sales relating to livestock containing antibiotics.[12]Another issue is the unnecessary use of antibiotics on livestock. Many farmers find it economically viable to prophylactically treat all their livestock rather than having to quarantine and treat once the infection becomes present.[13]Educating farmers on antibiotics might help curb this problem. Table 1 lists countries with the highest use of antibiotics in livestock and the drug resistant index. It is vital to identify ways to further reduce the amount of antibiotics used in livestock to prevent further progression of AR.
Table 1

Antibiotic use in livestock and in hospitals globally

LaboratoriesLivestock antibiotic use (mg/kg of livestock)[19]Medical antibiotic usage (defined daily dosage/1000 people)[20]Drug-resistant index[21]
Spain18214,63448
Italy15711,19147
France4113,04042
Australia1311,08835
The United States8810,29813
Canada119707810
Sweden847226

The drug-resistant index is a validated method of measuring the ability of antibiotics to effectively treat an infection that they are indicated for

Antibiotic use in livestock and in hospitals globally The drug-resistant index is a validated method of measuring the ability of antibiotics to effectively treat an infection that they are indicated for

PROPER ANTIBIOTIC STEWARDSHIP

There are several things that health professionals can do regarding proper antibiotic prescribing. They can be more discerning in how often they prescribe antibiotics, closely monitor for AR, keep a clean healthcare environment, talk with their patients regarding proper antibiotic use, and discuss ways to prevent infection including improving personal hygienic practices. Recent studies have indicated that 30%–70% of prescribed antibiotics at the hospital are suboptimal: using broad-spectrum antibiotics for empiric therapy when a narrower spectrum antibiotic would be appropriate.[141516]Consideration for earlier infectious disease referral should be undertaken not only for complicated cases but also for uncomplicated infections when there is a question regarding the optimal antibiotic prescription.[14]Proper education regarding the surrounding hospital community being treated as good levels of AR should be reviewed with the medical staff.[15]The United Kingdom currently uses specialized pharmacists to train the health-care professionals in antibiotic choice, thus reducing health care-associated infections, particularly Clostridium difficile infection.[16] Policy-makers can also do their part by creating methods to improve surveillance, prevent and control of outbreaks, promote regulation of cleanliness and hygiene in hospital settings, and distribute information to the public about AR. An example of a surveillance measure is the Centers for Disease Control and Prevention's AR maps which show AR [Figure 1].[17] Proper antibiotic stewardship is a combination of awareness of the individual prescriber, as well as education and research on a national and even global level. An example is legislation such as the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act (DISARM) introduced in 2019 to promote AR research.
Figure 1

(a) This figure shows the percentage of resistance (2014) in each state when comparing all health care-associated infections. Nevada and the Northeast states seem to have the highest rates of resistance. (b) This figure shows the percentage of resistance (2014) in each state when comparing all health care-associated infections. Southern states seem to have the highest rates of resistance

(a) This figure shows the percentage of resistance (2014) in each state when comparing all health care-associated infections. Nevada and the Northeast states seem to have the highest rates of resistance. (b) This figure shows the percentage of resistance (2014) in each state when comparing all health care-associated infections. Southern states seem to have the highest rates of resistance In conclusion, addressing these three problems of increasing incentives for research and production of antibiotics, decreasing environmental antibiotic usage, and proper antibiotic stewardship are vital to decreasing AR globally and locally. We believe that with continued collaborative efforts, we will hopefully reduce the threat of AR in the coming years.[18192021]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  13 in total

Review 1.  Antibiotic stewardship programmes--what's missing?

Authors:  Esmita Charani; Jonathan Cooke; Alison Holmes
Journal:  J Antimicrob Chemother       Date:  2010-09-16       Impact factor: 5.790

2.  Report reveals scope of US antibiotic resistance threat.

Authors:  Tracy Hampton
Journal:  JAMA       Date:  2013-10-23       Impact factor: 56.272

3.  Fix the antibiotics pipeline.

Authors:  Matthew A Cooper; David Shlaes
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

4.  Global trends in antimicrobial use in food animals.

Authors:  Thomas P Van Boeckel; Charles Brower; Marius Gilbert; Bryan T Grenfell; Simon A Levin; Timothy P Robinson; Aude Teillant; Ramanan Laxminarayan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-19       Impact factor: 11.205

Review 5.  A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail.

Authors:  Debra A Goff; Ravina Kullar; Ellie J C Goldstein; Mark Gilchrist; Dilip Nathwani; Allen C Cheng; Kelly A Cairns; Kevin Escandón-Vargas; Maria Virginia Villegas; Adrian Brink; Dena van den Bergh; Marc Mendelson
Journal:  Lancet Infect Dis       Date:  2016-11-18       Impact factor: 25.071

6.  Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement.

Authors:  Rosemary Wyber; Kathryn Taubert; Stephen Marko; Edward L Kaplan
Journal:  Glob Heart       Date:  2013-09-26

7.  Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews.

Authors:  Stephen Nurse-Findlay; Melanie M Taylor; Margaret Savage; Maeve B Mello; Sanni Saliyou; Manuel Lavayen; Frederic Seghers; Michael L Campbell; Françoise Birgirimana; Leopold Ouedraogo; Morkor Newman Owiredu; Nancy Kidula; Lee Pyne-Mercier
Journal:  PLoS Med       Date:  2017-12-27       Impact factor: 11.069

Review 8.  Antimicrobial Usage in Animal Production: A Review of the Literature with a Focus on Low- and Middle-Income Countries.

Authors:  Nguyen V Cuong; Pawin Padungtod; Guy Thwaites; Juan J Carrique-Mas
Journal:  Antibiotics (Basel)       Date:  2018-08-15

9.  Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index.

Authors:  Eili Y Klein; Katie K Tseng; Suraj Pant; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2019-04-11

10.  Antimicrobial Stewardship from Policy to Practice: Experiences from UK Antimicrobial Pharmacists.

Authors:  Mark Gilchrist; Paul Wade; Diane Ashiru-Oredope; Philip Howard; Jacqueline Sneddon; Laura Whitney; Hayley Wickens
Journal:  Infect Dis Ther       Date:  2015-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.